Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
- Associated Therapies
- -
PEARL Schizophrenia Maintenance
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 676
- Registration Number
- NCT01435928
- Locations
- 🇺🇸
Lousiana Clinical Research, LLC, Shreveport, Louisiana, United States
🇺🇸CRI Worldwide LLC, Willingboro, New Jersey, United States
🇺🇸FutureSearch Clinical Trials, LP, Dallas, Texas, United States
Major Depressive Disorder With Mixed Features - Extension
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01423253
- Locations
- 🇺🇸
St. Charles Psychiatric Associates/Midwest Research Group, St. Charles, Missouri, United States
🇺🇸Village Clinical Research Inc., New York, New York, United States
🇺🇸Stanford -VA Palo Alto Health Care System, Palo Alto, California, United States
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01421134
- Locations
- 🇷🇸
Special Hospital for Psychiatric Diseases "Dr Slavoljub Bakalovic", Vrsac, Serbia
🇷🇸Special Hospital for Psychiatric Diseases "Sveti Vracevi", Vojvodina, Serbia
🇺🇸Clinical Innovations Inc., Riverside, California, United States
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 965
- Registration Number
- NCT01358357
- Locations
- 🇺🇸
AXIS Clinical Trials, Los Angeles, California, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Behavioral Research Specialists, LLC, Glendale, California, United States
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT01284517
- Locations
- 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸Clinical Innovations inc., Santa Ana, California, United States
🇺🇸Collaborative Neuroscience Network, Torrance, California, United States
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01143090
- Locations
- 🇺🇸
Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸FutureSearch Trials of Dallas, Dallas, Texas, United States
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 244
- Registration Number
- NCT01143077
- Locations
- 🇺🇸
Collaborative Neuroscience Network, South Bay, Torrance, California, United States
🇺🇸Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States
🇺🇸CRI Worldwide - Kirkbride Center, Philadelphia, Pennsylvania, United States
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01082276
- Locations
- 🇺🇸
PAREXEL Clinical Pharmacology Research Unit, Baltimore, Maryland, United States
Midazolam Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01082263
- Locations
- 🇺🇸
CCT/Parexel, Culver City, California, United States
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01082250
- Locations
- 🇺🇸
California Clinical Trials (CCT), Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.